Vulva Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VLV032 MIFTS: 48	Vulva Cancer Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Vulva Cancer

MalaCards integrated aliases for Vulva Cancer:

Name: Vulva Cancer ¹² ¹⁵

Vulva Carcinoma ¹² ⁵⁵ ¹⁵

Vulvar Cancer ⁵³ ³⁷ ⁴³

Malignant Neoplasm of Vulva ¹² ⁷³

Carcinoma of Vulva ¹² ⁷³

Vulvar Neoplasms ⁴⁴ ⁷³

Malignant Tumor of Vulva ¹²

Malignant Vulvar Tumor ¹²

Neoplasm of Vulva ¹²

Vulvar Carcinoma ¹²

Vulval Neoplasm ¹²

Vulvar Neoplasm ¹²

Vulval Cancer ¹²

Vulvar Tumor ¹²

Ca Vulva ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of vulva

Malignant neoplasm: Vulva, unspecified

External Ids:

Disease Ontology ¹² DOID:1245 DOID:1294

ICD10 ³³ C51 C51.9

ICD9CM ³⁵ 184.4

MeSH ⁴⁴ D014846

NCIt ⁵⁰ C3443 C7502 C4866

SNOMED-CT ⁶⁸ 94143002

KEGG ³⁷ H00029

UMLS ⁷³ C0042995 C0375071 C0677055

Sources

Summaries for Vulva Cancer

MedlinePlus : ⁴³ Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause symptoms at first. However, see your doctor for testing if you notice A lump in the vulva Vulvar itching or tenderness Bleeding that is not your period Changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer You are at greater risk if you've had a human papillomavirus (HPV) infection or have a history of genital warts. Your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. Treatment varies, depending on your overall health and how advanced the cancer is. It might include surgery, radiation therapy, chemotherapy, or biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Vulva Cancer, also known as vulva carcinoma, is related to vulva adenocarcinoma and vulva squamous cell carcinoma, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are L1CAM interactions and Glioblastoma Multiforme. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and lymph node.

Disease Ontology : ¹² A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

NIH Rare Diseases : ⁵³ Vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina. Symptoms of vulvar cancer may consist of a lump (mass), itching, or unusual bleeding. Though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing vulvar cancer. Treatment may include laser therapy, surgery, chemotherapy, or radiation therapy.

Wikipedia : ⁷⁶ Vulvar cancer is a malignant, invasive growth in the vulva, or the outer portion of the female genitals.... more...

Sources

Related Diseases for Vulva Cancer

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)

#	Related Disease	Score	Top Affiliating Genes
1	vulva adenocarcinoma	31.3	CDKN2A KRT7 LINC01191 UPK3A
2	vulva squamous cell carcinoma	31.2	CDKN2A PLXDC2 SERPINB3 SH3GL2 TP53
3	squamous cell carcinoma	30.3	CDKN2A EGFR SERPINB3 TP53
4	verrucous carcinoma	30.3	CDKN2A TP53
5	vulvar intraepithelial neoplasia	30.1	KRT7 TP53
6	anogenital venereal wart	30.0	CDKN2A TP53
7	vulvar disease	29.9	CDKN2A KRT13 KRT7 LINC01191 MIR3147 PLXDC2
8	papilloma	29.9	CDKN2A KRT13 KRT7 TP53
9	in situ carcinoma	29.9	CDKN2A EGFR TP53
10	vulvar dystrophy	29.7	CDKN2A LINC01191
11	small cell carcinoma	29.7	CDKN2A EGFR KRT7 TP53
12	vulva verrucous carcinoma	11.5
13	vulvar basal cell carcinoma	11.1
14	vaginal disease	11.1
15	bartholin's gland benign neoplasm	11.1
16	vulva basal cell carcinoma	11.1
17	vulvar sebaceous carcinoma	11.1
18	vulvar eccrine porocarcinoma	11.1
19	vulvar clear cell hidradenocarcinoma	11.1
20	vulvar glandular tumor	11.0
21	vulvar melanoma	11.0
22	vulvar sarcoma	11.0
23	clitoris cancer	11.0
24	brain ependymoma	10.3	EGFR TP53
25	malignant peritoneal mesothelioma	10.3	CDKN2A EGFR
26	peritoneal mesothelioma	10.3	CDKN2A EGFR
27	anaplastic oligodendroglioma	10.3	CDKN2A EGFR
28	bladder squamous cell carcinoma	10.3	CDKN2A TP53
29	keratinizing squamous cell carcinoma	10.3	CDKN2A TP53
30	benign breast adenomyoepithelioma	10.3	EGFR KRT7
31	spitz nevus	10.3	CDKN2A TP53
32	breast squamous cell carcinoma	10.3	EGFR TP53
33	inverted transitional papilloma	10.2	CDKN2A KRT7
34	scrotal carcinoma	10.2	CDKN2A TP53
35	oncocytic breast carcinoma	10.2	EGFR KRT7
36	bartholin's gland disease	10.2	CDKN2A TP53
37	anal squamous cell carcinoma	10.2	CDKN2A TP53
38	microglandular adenosis	10.2	EGFR TP53
39	megaesophagus	10.2	CDKN2A TP53
40	gastric adenosquamous carcinoma	10.2	CDKN2A TP53
41	malignant spiradenoma	10.2	KRT7 TP53
42	spiradenoma	10.2	KRT7 TP53
43	cervix uteri carcinoma in situ	10.2	CDKN2A TP53
44	uterus carcinoma in situ	10.2	CDKN2A TP53
45	adenoid basal cell carcinoma	10.2	CDKN2A KRT7
46	oral leukoplakia	10.2	CDKN2A TP53
47	bile duct adenoma	10.2	CDKN2A KRT7
48	endocervical carcinoma	10.2	CDKN2A KRT7
49	nasal cavity cancer	10.2	CDKN2A KRT7
50	meningeal melanomatosis	10.2	CDKN2A TP53

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Clitoris Cancer
Hypertension, Essential	Localized Scleroderma
Vaginal Cancer	Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:

Sources

Symptoms & Phenotypes for Vulva Cancer

UMLS symptoms related to Vulva Cancer:

pelvic pain, pruritus vulvae

Sources

Drugs & Therapeutics for Vulva Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Octreotide

Approved, Investigational

Phase 3

83150-76-9

383414 6400441

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Dehydroepiandrosterone

Approved, Investigational, Nutraceutical

Phase 3

53-43-0

5881

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Cola

Phase 3,Phase 2,Phase 1

Liver Extracts

Phase 3,Phase 2,Phase 1

Coagulants

Phase 3

Hemostatics

Phase 3

Fibrin Tissue Adhesive

Phase 3

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Vaccines

Phase 3,Phase 2,Phase 1,Not Applicable

Gastrointestinal Agents

Phase 3,Phase 1

Antineoplastic Agents, Hormonal

Phase 3

Central Nervous System Depressants

Phase 3

Adjuvants, Anesthesia

Phase 3

Anesthetics, Intravenous

Phase 3

Analgesics, Opioid

Phase 3

Peripheral Nervous System Agents

Phase 3,Phase 2,Phase 1

Anesthetics, General

Phase 3

Analgesics

Phase 3,Phase 2,Phase 1

Narcotics

Phase 3

Anesthetics

Phase 3

Adjuvants, Immunologic

Phase 3,Phase 2,Phase 1,Not Applicable

DHEA (Dehydroepiandrosterone)

Phase 3

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Indinavir

Approved

Phase 2

150378-17-9

5362440

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Clobetasol

Approved, Experimental, Investigational

Phase 2

25122-46-7, 25122-41-2

5311051 32798

Tacrolimus

Approved, Investigational

Phase 2

104987-11-3

445643 439492

Pimecrolimus

Approved, Investigational

Phase 2

137071-32-0

6447131 17753757

Fondaparinux

Approved, Investigational

Phase 2

104993-28-4

Gemcitabine

Approved

Phase 2,Phase 1

95058-81-4

60750

Imiquimod

Approved, Investigational

Phase 2,Not Applicable

99011-02-6

57469

Nivolumab

Approved

Phase 2,Phase 1

946414-94-4

Daratumumab

Approved

Phase 1, Phase 2

945721-28-8

Fludarabine

Approved

Phase 1, Phase 2,Phase 2

75607-67-9, 21679-14-1

30751

Aldesleukin

Approved

Phase 1, Phase 2

85898-30-2, 110942-02-4

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

6055-19-2, 50-18-0

2907

Bupropion

Approved

Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 2

51-61-6, 62-31-7

681

Pembrolizumab

Approved

Phase 2

1374853-91-4

Irinotecan

Approved, Investigational

Phase 2

100286-90-6, 97682-44-5

60838

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Serine

Approved, Nutraceutical

Phase 2

56-45-1

5951

Camptothecin

Experimental

Phase 2,Phase 1

7689-03-4

Anti-HIV Agents

Phase 2,Phase 1

HIV Protease Inhibitors

Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 2

Interventional clinical trials:

(show top 50) (show all 133)

#	Name	Status	NCT ID	Phase	Drugs
1	Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva	Completed	NCT00003325	Phase 3
2	Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes	Completed	NCT00898352	Phase 3
3	Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva	Completed	NCT00028951	Phase 3	fibrin sealant
4	Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage	Completed	NCT00224744	Phase 3
5	Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)	Completed	NCT00092521	Phase 3
6	Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence	Completed	NCT01148290	Phase 3
7	A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)	Completed	NCT01047345	Phase 3
8	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)	Completed	NCT00543543	Phase 3
9	Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)	Completed	NCT03158220	Phase 3
10	A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)	Completed	NCT00090220	Phase 3
11	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis	Completed	NCT00033605	Phase 3	octreotide acetate
12	GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)	Completed	NCT01245764	Phase 3
13	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
14	A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)	Completed	NCT00092547	Phase 3
15	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	Recruiting	NCT02997553	Phase 3	Indocyanine green;Technetium99
16	A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)	Active, not recruiting	NCT00943722	Phase 3
17	Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam	Active, not recruiting	NCT03546842	Phase 3
18	Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms	Active, not recruiting	NCT01376349	Phase 3	prasterone
19	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva	Terminated	NCT00006096	Phase 3	cisplatin
20	Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer	Terminated	NCT00577317	Phase 3
21	Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer	Unknown status	NCT00905658	Phase 2
22	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
23	Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva	Completed	NCT00014599	Phase 2	paclitaxel
24	Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva	Completed	NCT00068406	Phase 2	Cisplatin
25	The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence	Completed	NCT01986725	Phase 2
26	Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar	Completed	NCT00476476	Phase 2	Erlotinib
27	Effectiveness of an Individualized Symptom Education Program (ISEP)	Completed	NCT00275353	Phase 2
28	Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers	Completed	NCT00545792	Phase 2	Avastin
29	Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus	Completed	NCT00393263	Phase 2	pimecrolimus and clobetasol;clobetasol 0.05% cream
30	A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)	Completed	NCT00551187	Phase 2
31	Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)	Completed	NCT00520598	Phase 2	Comparator: V505 formulation 2;Comparator: V505 formulation 2
32	Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer	Completed	NCT00381888	Phase 2	fondaparinux sodium
33	Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies	Completed	NCT01079832	Phase 2
34	Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer	Completed	NCT01764802	Phase 2
35	Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva	Recruiting	NCT01595061	Phase 2	Cisplatin;Gemcitabine Hydrochloride
36	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
37	Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers	Recruiting	NCT03403465	Phase 2
38	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	Recruiting	NCT02488759	Phase 1, Phase 2	Nivolumab;Ipilimumab;Relatlimab;Daratumumab
39	Image-Guided Gynecologic Brachytherapy	Recruiting	NCT02993900	Phase 2
40	E7 TCR T Cells for Human Papillomavirus-Associated Cancers	Recruiting	NCT02858310	Phase 1, Phase 2	Aldesleukin;Fludarabine;Cyclophosphamide
41	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers	Recruiting	NCT03439085	Phase 2
42	Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer	Recruiting	NCT03180294	Phase 2	Bupropion Hydrochloride
43	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Recruiting	NCT02628067	Phase 2
44	Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)	Recruiting	NCT03180684	Phase 2	Imiquimod 5% cream
45	Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy	Active, not recruiting	NCT01406769	Phase 2
46	Image-Guided Gynecologic Brachytherapy	Active, not recruiting	NCT01399658	Phase 2
47	Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva	Terminated	NCT00003525	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
48	Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer	Terminated	NCT00106262	Phase 2	Velcade (bortezomib);Irinotecan
49	Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Withdrawn	NCT03220009	Phase 2
50	Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	Unknown status	NCT00066404	Phase 1

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Sources

Genetic Tests for Vulva Cancer

Sources

Anatomical Context for Vulva Cancer

MalaCards organs/tissues related to Vulva Cancer:

⁴¹

Skin, Testes, Lymph Node, Cervix, Lung, Brain, Liver

Sources

Publications for Vulva Cancer

Articles related to Vulva Cancer:

(show all 22)

#	Title	Authors	Year
1	Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. ( 29420364 )	Froeding L.P....Jensen P.T.	2018
2	Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the &quot;too difficult to do&quot; box? ( 28034465 )	O'Donnell R.L....Naik R.	2017
3	Vulva cancer in Ghana - Review of a hospital based data. ( 28409179 )	Dadzie MA...Vanderpuye V	2017
4	The Added Value of Pathology Review in Vulva Cancer: Results From a Population-based Cohort Study. ( 27513080 )	Barbera L....Khalifa M.	2016
5	The number of removed lymph nodes by inguinofemoral lymphadenectomy: impact on recurrence rates in patients with vulva carcinoma. ( 26498758 )	Diehl A...Puppe J	2016
6	Bardet-Biedl syndrome with vulva carcinoma presented with acute renal failure: a case report. ( 27418769 )	Sari F...Yilmaz B	2015
7	Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. ( 25225572 )	Simbiri K.O....Robertson E.S.	2014
8	Could Sentinel Node Mapping of the Groin Cause Extranodal Metastasis in Vulva Cancer? ( 25412581 )	Abdul Wahab N.A....Gleeson N.	2014
9	Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. ( 23725140 )	Ngamkham J....Swangvaree S.S.	2013
10	The comparative study of former and latest FIGO staging of vulva cancer. ( 22487921 )	Sun X....Cheng H.	2012
11	Assessment of promising protein markers for vulva cancer. ( 19509584 )	Fons G....van der Velden J.	2009
12	An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. ( 17006101 )		2006
13	Is there a role for magnetic resonance imaging in the evaluation of inguinal lymph node metastases in patients with vulva carcinoma? ( 16859737 )	Bipat S...Stoker J	2006
14	Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. ( 16149671 )		2005
15	Correspondence re: Weiderpass et al., Alcoholism and risk of cancer of cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev., 10: 899-901, 2001. ( 11895888 )	Chiaffarino F....La Vecchia C.	2002
16	Response to &quot;Inguinal node status by ultrasound in vulva cancer&quot; (Abang Mohammed et al. Gynecol Oncol 2000;77:93-6). ( 11277664 )	Moskovic E.	2001
17	Inguinal node status by ultrasound in vulva cancer. ( 10739696 )	Abang Mohammed D.K....Monaghan J.M.	2000
18	Cervical and vulva cancer: changes in FIGO definitions of staging. ( 8624311 )	Shepherd J.H.	1996
19	T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. ( 7774837 )	Siller B.S....Austin J.M.	1995
20	Adenocarcinoma of the mammary-like glands of the vulva: a concept unifying sweat gland carcinoma of the vulva, carcinoma of supernumerary mammary glands and extramammary Paget's disease. ( 8040464 )	van der Putte SC...van Gorp LH	1994
21	Choice of operation for vulva carcinoma. ( 5514782 )	Shingleton HM...Fowler WC	1970
22	A CASE OF METASTASIS OF VULVA CARCINOMA IN THE DEEP INGUINAL REGION, DIAGNOSED BY CYTOLOGY. ( 14074204 )	FIGUEIREDO F	1963

Sources

Genes for Vulva Cancer

Genes related to Vulva Cancer (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	24.09	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	8912181 18618485 11262056
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.68	DISEASES inferred ¹⁵ ¹⁵
3	TP53	Tumor Protein P53	Protein Coding	21.8	DISEASES inferred ¹⁵ ¹⁵
4	KRT13	Keratin 13	Protein Coding	20.35	DISEASES inferred ¹⁵ ¹⁵
5	KRT7	Keratin 7	Protein Coding	19.89	DISEASES inferred ¹⁵ ¹⁵
6	PLXDC2	Plexin Domain Containing 2	Protein Coding	19.43	DISEASES inferred ¹⁵ ¹⁵
7	UPK3A	Uroplakin 3A	Protein Coding	18.74	DISEASES inferred ¹⁵ ¹⁵
8	SERPINB3	Serpin Family B Member 3	Protein Coding	18.52	DISEASES inferred ¹⁵ ¹⁵
9	SCN10A	Sodium Voltage-Gated Channel Alpha Subunit 10	Protein Coding	18.51	DISEASES inferred ¹⁵ ¹⁵
10	SH3GL2	SH3 Domain Containing GRB2 Like 2, Endophilin A1	Protein Coding	18.46	DISEASES inferred ¹⁵ ¹⁵
11	LINC01191	Long Intergenic Non-Protein Coding RNA 1191	RNA Gene	17.14	DISEASES inferred ¹⁵ ¹⁵
12	MIR3147	MicroRNA 3147	RNA Gene	11.45	DISEASES inferred ¹⁵ ¹⁵

Sources

Variations for Vulva Cancer

Cosmic variations for Vulva Cancer:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM498	HRAS	skin,genital,carcinoma,NS	c.182A>T	p.Q61L	11:533874-533874	7
2	COSM12296	TP53	skin,lip,carcinoma,NS	c.292C>T	p.P98S	17:7676077-7676077	6
3	COSM10662	TP53	skin,lip,carcinoma,NS	c.743G>A	p.R248Q	17:7674220-7674220	6
4	COSM17598	PTCH1	skin,lip,carcinoma,NS	c.550C>T	p.Q184*	9:95485719-95485719	6
5	COSM26363	PTCH1	skin,lip,carcinoma,NS	c.2446C>T	p.Q816*	9:95467230-95467230	6

Sources

Expression for Vulva Cancer

Search GEO for disease gene expression data for Vulva Cancer.

Sources

Pathways for Vulva Cancer

Pathways related to Vulva Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	L1CAM interactions ⁶⁶ Show member pathways CHL1 interactions ⁶⁶ Neurofascin interactions ⁶⁶ NrCAM interactions ⁶⁶	11.53	EGFR SCN10A SH3GL2
2	Glioblastoma Multiforme ⁶⁴	11.38	CDKN2A EGFR TP53
3	Gastric Cancer Network 2 ¹	10.95	EGFR TP53
4	Oncogene Induced Senescence ⁶⁶	10.91	CDKN2A TP53
5	Photodynamic therapy-induced AP-1 survival signaling. ¹	10.84	CDKN2A EGFR TP53
6	Bladder cancer ³⁷ ¹	10.79	CDKN2A EGFR TP53 UPK3A
7	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁴	10.71	CDKN2A TP53
8	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.66	CDKN2A TP53

Sources

GO Terms for Vulva Cancer

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of epidermal growth factor receptor signaling pathway	GO:0042059	9.16	EGFR SH3GL2
2	replicative senescence	GO:0090399	8.96	CDKN2A TP53
3	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	8.62	EGFR TP53

Molecular functions related to Vulva Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	8.92	CDKN2A EGFR SH3GL2 TP53

Sources

Sources for Vulva Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia